TY - BOOK AU - Jamil, Umer TI - Dual antithrombotic plus adjunctive antiinflammatory therapy to improve cardiovascular outcome in atrial fibrillation patients with concurrent acute coronary syndrome: A triple-pathway strategy SN - 0306-9877 PY - 2018/// KW - *Acute Coronary Syndrome/dt [Drug Therapy] KW - *Anti-Inflammatory Agents/ad [Administration & Dosage] KW - *Atrial Fibrillation/dt [Drug Therapy] KW - *Fibrinolytic Agents/ad [Administration & Dosage] KW - Acute Coronary Syndrome/co [Complications] KW - Anticoagulants/ae [Adverse Effects] KW - Arrhythmias, Cardiac/dt [Drug Therapy] KW - Aspirin/tu [Therapeutic Use] KW - Atrial Fibrillation/co [Complications] KW - Cardiovascular System KW - Comorbidity KW - Drug Therapy, Combination KW - Hemorrhage/ci [Chemically Induced] KW - Humans KW - Interleukin-1beta/me [Metabolism] KW - Models, Theoretical KW - Platelet Aggregation Inhibitors KW - Randomized Controlled Trials as Topic KW - Stents KW - Stroke/co [Complications] KW - Warfarin/tu [Therapeutic Use] KW - MedStar Union Memorial Hospital KW - Medicine KW - Journal Article N2 - Copyright (c) 2018 Elsevier Ltd. All rights reserved; The concurrence of atrial fibrillation and acute coronary syndrome poses a conundrum in the antithrombotic management as intensification of anticoagulation or antiplatelet therapy inevitably comes at the price of an increased bleeding risk. Various antithrombotic combinations have been attempted to prevent the recurrent cardiovascular events, however, there has been limited success in effective risk reduction for this high risk population. Given the overarching effect of interleukin 1beta-driven inflammation on the arrhythmogenesis, thrombogenesis, and hypercoagulability, we hypothesize that the triple-pathway strategy (i.e., incorporating antiinflammatory therapy into anticoagulant and antiplatelet therapy) would grant incremental cardiovascular benefits for atrial fibrillation patients with coexisting acute coronary syndrome and stent placement UR - https://dx.doi.org/10.1016/j.mehy.2018.02.036 ER -